News | Image Guided Radiation Therapy (IGRT) | October 05, 2018

ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy

ViewRay MRIdian Linac system helps prolong survival and reduce complications

ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy

October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay Inc. — maker of MRIdian, the world's first U.S. Food and Drug Administration (FDA)-cleared, MRI-guided radiation therapy system — and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the Sept. 28 symposium and panel discussion.

Presenters and panel participants included:

  • Minesh Mehta, M.D., chief of radiation oncology, and Michael Chuong, M.D., director of radiation oncology clinical research and education, at Miami Cancer Institute, a part of Baptist Health South Florida;
  • Michael Bassetti, M.D., Ph.D., assistant professor of radiation oncology at University of Wisconsin, Carbone Cancer Center; and
  • Raymond Wynn, M.D., FACR, professor and vice chair of network operations in the department of radiation oncology at Loyola University Medical Center.

"Seldom do we see this much excitement around a technology," Mehta said. "For the first time, we're able to see high-contrast soft tissue images that clearly delineate tumors from the surrounding healthy organs. This allows us to deliver radiation more precisely, and in some cases, may even allow us to increase the radiation dose to more aggressively fight the cancer."

"MRIdian has taken much of the guesswork out of radiation therapy. Its visualization and adaptive abilities are of benefit in treating many types of cancer, but they are especially vital when treating tumors that move significantly during treatment, such as tumors in the lung or liver. We can now watch the changes within the body in real-time and respond accordingly," Chuong said. "This leads to more accurate treatment of the tumor and minimizes irradiation of nearby normal tissues, potentially reducing the side effects."

"This technology is a true game-changer, and we are honored to be the first center in Illinois and first community practice nationwide to offer it to our patients," Wynn said. "MRI-guided radiation therapy enables us to deliver more accurate and effective radiation doses, in fewer sessions, while sparing healthy tissue. This now makes what was science fiction a science reality."

"Seeing the tumor and surrounding healthy tissues and organs in great detail allows us to adapt the treatment in order to improve dosing and accuracy," Bassetti said. "Early results in pancreatic cancer suggest that the ability to deliver higher radiation doses with adaptive MRI-guided radiation therapy may improve patient survival while maintaining low toxicity. We look forward to further investigating these promising outcomes."

ViewRay has announced the launch of a multi-center prospective clinical trial in pancreatic cancer to investigate the robustness of encouraging early data in patients treated with MRI-guided radiation therapy. The study aims to track patient survival and quality of life over a five-year period. The trial is expected to open enrollment in the coming weeks.

Watch the VIDEO: MRI-Guided Radiation Therapy Trial for Pancreatic Cancer, an interview with Benjamin Movsas, M.D., and Carrie Glide-Hurst, Ph.D., of Henry Ford Hospital System, about the ViewRay pancreatic cancer trial.

For more information: www.viewray.com

 

Related Content

Radiographer Apollo Exconde with his Lego concept open MRI for patient education.

Radiographer Apollo Exconde with his Lego concept open MRI for patient education.

News | Patient Engagement | November 11, 2019
November 11, 2019 — Radiographer Apollo Exconde...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
The introduction of liquid helium free, high-end MRI systems by MR Solutions substantially reduces the environmental impact
News | Magnetic Resonance Imaging (MRI) | November 05, 2019
November 5, 2019 — Environmental impact is becoming a significant factor in the selection of suppliers even in precli
MRI control room at Centra DuPage Hospital
News | Magnetic Resonance Imaging (MRI) | November 04, 2019
November 4, 2019 — Traditional image-guided procedures remained restricted to the limitation of physicians referring
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
The Neuroreader software program quantifies brain volume in study participants with TBI

The Neuroreader software program quantifies brain volume in study participants with TBI. Image courtesy of UCLA Health.

News | Clinical Trials | October 29, 2019
October 29, 2019 — A UCLA-led...
An example of a semitruck trailer-based mobile MRI suite.

An example of a semitruck trailer-based mobile MRI suite, similar to the one involved in the accident.

Feature | Magnetic Resonance Imaging (MRI) | October 25, 2019 | Dave Fornell
A radiology nurse was seriously injured Oct. 23 at Sunderby Hospital in Luleå, located in northern Sweden, when caught...
NVIDIA and King's College London Debut First Privacy-preserving Federated Learning System

Image courtesy of NVIDIA

News | Artificial Intelligence | October 23, 2019
To help advance medical research while preserving data privacy and improving patient outcomes for brain tumor...